The Oncologist
@OncJournal
The Oncologist Journal focuses on medical and practice issues of busy oncology, hematology and radiation professionals to aid in better cancer patient care.
Drs @UGrewalMD and @TimothyJBrownMD discuss the evolving treatment of #stmcsm with new targeted agents 🎯like zolbetuximab for #HER2- but #CLDN182+ disease. They describe 4 biomarker (MSI/MMR, HER2, PD-L1, CLDN18.2) profiles that guide therapy #GIonc doi.org/10.1093/oncolo…
Dr. @KelseyLauMin et al describe the⬆️#supponccare needs in #LARCpatients #crcsmundergoing complex treatment such as chemoradiation and surgery. They emphasize ongoing informational gaps needing intervention #pallonc @RyanNipp @aparna1024 @Areejmd doi.org/10.1093/oncolo…
A review of device therapy in #supponc from #coolingdevices to address #alopecia to #TEAS to impact chemo induced nausea and vomiting #CINV, the authors also describe financial barriers to #pallonc and emphasize education, research, and policy. doi.org/10.1093/oncolo…
‘@kspencer725 and King bring a review of #MDM2 amplification as an emerging target 🎯 across #btcsm Therapies restoring p53 function via #MDM2inhibition show promise but remain investigational #GIonc doi.org/10.1093/oncolo…
Dr @guptaarjun90 et al show contact days—days w/ healthcare contact—correlate w/ both #direct & #indirectcosts in lymphoma trials #fintox. They may be a scalable proxy for health system costs but don't fully capture #patient and #caregiver burden #supponc doi.org/10.1093/oncolo…
This article highlights the lifecycle of each myeloma regimen added to NCCN guidelines, showing that guidelines remain relevant, adding new regimens w/ promising early phase data, & removing regimens that become obsolete over time. doi.org/10.1093/oncolo…
Patient HSUVs are a key measure of QoL in mCRPC. This article reports that patient utilities decline as patients progress through lines of therapy. These findings can help inform economic models & support drug reimbursement in mcRPC. #mCRPC #prostatecancer doi.org/10.1093/oncolo…
Dr @ChrisCannMD & team show biweekly TAS-102 #BiTS in #crcsm ⬇️grade ≥3 neutropenia & anemia and maintained similar #PFS (4.2mo) & #OS (9.2mo) vs standard dosing. This schedule may improve tolerability & support combination 💊💉#Bev #GIonc doi.org/10.1093/oncolo…
In this Phase 0 study, #bethanechol was well tolerated in resectable #pancsm and showed #antiinflammatoryeffects, including ⬇️IL-18 and Granzyme B+ cells. These findings support further study of #parasympatheticmodulation #GIonc @susanebates doi.org/10.1093/oncolo…
'@MargaretWheless et al show that Pemigatinib 🎯showed no #ORR n FGF/FGFR-altered #crcsm. Most had mutations/amplifications, not fusions #GIonc @KristenCiombor @GIcancerDoc doi.org/10.1093/oncolo…
Palbociclib & endocrine therapy for metastatic breast cancer can increase life expectancy but also increases fatigue, possibly lowering QoL. Biological markers & behavioral factors may help identify at-risk populations & optimize treatment plans. doi.org/10.1093/oncolo…
#BRCA 1/2 mutation carriers could represent a higher-risk population for anthracyclines-induced #cardiotoxicity in patients with HER2-negative early breast cancer. #CardioOnc #BreastCancer #CardioTwitter #BRCAN doi.org/10.1093/oncolo…
'@anwilkinson and @JeanSeely working with @StatCan_eng show women of racial and ethnic groups other than White are diagnosed with breast cancer at younger ages and more advanced stages. doi.org/10.1093/oncolo…
Study finds irAEs in NSCLC patients linked to better survival outcomes regardless of race. Insights into diverse patient responses crucial for personalized care. #NSCLC #immunotherapy #healthdisparities @amrradwan05 @Jani_Chinmay @umittapan_LC_MD doi.org/10.1093/oncolo…
Risk-sharing agreement (RSA) study reveals that RSAs alleviate financial burden of immunotherapy, fostering a more sustainable healthcare model with up to 40% cost reduction. @ogarrieta doi.org/10.1093/oncolo…
Opioid use and adverse health effects in breast cancer survivors @KPSCalResearch doi.org/10.1093/oncolo…
Complete response to multimodal temporal therapy in adv pancreatic cancer provides proof-of-concept for the Nant Cancer Vaccine: tumor-targeted chemotherapy + IL-15 superagonist Anktiva & natural killer cell immunotherapy to induce immunogenic cell death. doi.org/10.1093/oncolo…
Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma @DrKaramKhaddour @InscoLab doi.org/10.1093/oncolo…
Benchmark study evaluating adequacy and success rates of comprehensive genomic profiling in tissue and plasma samples in a real-world setting. @DougLinMD doi.org/10.1093/oncolo…
Results of the first real-world study of 1st-line CGD in patients w/ BTC w/ early relapse. Analysis suggests that this group can benefit from CGD in terms of OS, PFS, and ORR, with a good safety profile. @casadei_gardini #Cholangiocarcinoma #Immunotherapy doi.org/10.1093/oncolo…
